Document Detail


Complications associated with combined use of abciximab and an intracoronary thrombolytic agent (urokinase or tissue-type plasminogen activator).
MedLine Citation:
PMID:  9723644     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
A potent platelet inhibitor combined with an intracoronary thrombolytic agent is aggressive therapy that may be used for high-risk, complex, refractory thrombotic coronary lesions. A retrospective review of the records of 56 patients who received abciximab plus an intracoronary thrombolytic agent during a coronary interventional procedure did not reveal a prohibitive incidence of major bleeding with this combination therapy.
Authors:
R A Yaryura; M Zaqqa; J J Ferguson
Related Documents :
2646894 - Thrombolytic agents in early myocardial infarction.
16911924 - Successful thrombolytic therapy for bilateral renal infarction: a case report.
9447334 - The gusto trial and the open artery theory.
9169894 - Thrombolytic therapy for eligible elderly patients with acute myocardial infarction.
19408074 - Use of levosimendan in patients with ischemic heart disease following mechanical reperf...
9565514 - Dobutamine stress echocardiography in anomalous left coronary artery.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The American journal of cardiology     Volume:  82     ISSN:  0002-9149     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  1998 Aug 
Date Detail:
Created Date:  1998-09-16     Completed Date:  1998-09-16     Revised Date:  2013-05-24    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  518-9     Citation Subset:  AIM; IM    
Affiliation:
Department of Cardiology, St. Luke's Episcopal Hospital/Texas Heart Institute, Houston, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Angioplasty, Balloon, Coronary*
Antibodies, Monoclonal / adverse effects*
Coronary Disease / drug therapy*,  therapy
Drug Therapy, Combination
Female
Humans
Immunoglobulin Fab Fragments / adverse effects*
Male
Middle Aged
Plasminogen Activators / adverse effects*
Platelet Aggregation Inhibitors / adverse effects*
Postoperative Hemorrhage / chemically induced*
Retrospective Studies
Tissue Plasminogen Activator / adverse effects
Urokinase-Type Plasminogen Activator / adverse effects
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Immunoglobulin Fab Fragments; 0/Platelet Aggregation Inhibitors; EC 3.4.21.-/Plasminogen Activators; EC 3.4.21.68/Tissue Plasminogen Activator; EC 3.4.21.73/Urokinase-Type Plasminogen Activator; X85G7936GV/abciximab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Predictive value of C-reactive protein after successful coronary-artery stenting in patients with st...
Next Document:  Dipyridamole-dobutamine stress with Tc-99m sestamibi tomographic myocardial perfusion imaging.